GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyundai Bioscience Co Ltd (XKRX:048410) » Definitions » Gross Profit

Hyundai Bioscience Co (XKRX:048410) Gross Profit : ₩11,865 Mil (TTM As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Hyundai Bioscience Co Gross Profit?

Hyundai Bioscience Co's gross profit for the three months ended in Dec. 2024 was ₩145 Mil. Hyundai Bioscience Co's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was ₩11,865 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Hyundai Bioscience Co's gross profit for the three months ended in Dec. 2024 was ₩145 Mil. Hyundai Bioscience Co's Revenue for the three months ended in Dec. 2024 was ₩366 Mil. Therefore, Hyundai Bioscience Co's Gross Margin % for the quarter that ended in Dec. 2024 was 39.67%.

Hyundai Bioscience Co had a gross margin of 39.67% for the quarter that ended in Dec. 2024 => Competition eroding margins

During the past 13 years, the highest Gross Margin % of Hyundai Bioscience Co was 78.84%. The lowest was 29.96%. And the median was 46.16%.


Hyundai Bioscience Co Gross Profit Historical Data

The historical data trend for Hyundai Bioscience Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyundai Bioscience Co Gross Profit Chart

Hyundai Bioscience Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,562.67 3,520.76 2,683.26 5,041.18 11,865.28

Hyundai Bioscience Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 368.30 2,808.33 8,954.95 -43.02 145.01

Competitive Comparison of Hyundai Bioscience Co's Gross Profit

For the Biotechnology subindustry, Hyundai Bioscience Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyundai Bioscience Co's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyundai Bioscience Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Hyundai Bioscience Co's Gross Profit falls into.


;
;

Hyundai Bioscience Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Hyundai Bioscience Co's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=15050.025 - 3184.749
=11,865

Hyundai Bioscience Co's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=365.537 - 220.523
=145

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩11,865 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Hyundai Bioscience Co's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=145 / 365.537
=39.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Hyundai Bioscience Co  (XKRX:048410) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Hyundai Bioscience Co had a gross margin of 39.67% for the quarter that ended in Dec. 2024 => Competition eroding margins


Hyundai Bioscience Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Hyundai Bioscience Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyundai Bioscience Co Business Description

Traded in Other Exchanges
N/A
Address
150 North-Ahyun Road, 3rd Floor Academic Cooperation Building, Ehwa Women’s University, Seodaemun-gu, Seoul, KOR
Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.

Hyundai Bioscience Co Headlines

No Headlines